NCT06627322 - A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH) | Biotech Hunter

Enrollment

5,950

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions

Type 2 Diabetes

Interventions

DRUG

Dual-combination therapy

Group 1: Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Any oral antiglycemic drugs on the market.

DRUG

Triple-combination therapy

Group 2: Metformin/SGLT2i/DPP-4i-based triple-cobmination therapy, or Group 3: Metformin/SGLT2i/Thiazolidinedione-based triple-cobmination therapy Any oral antiglycemic drugs on the market.

DEVICE

Dexcom G7, Pasta

Real-time continous glucose monitoring system (CGMS) Device (sensor): Dexcom G7 Device (software): Kakaohealthcare Pasta Barozen Fit is also available.

Trial Locations (2)

42415

NOT_YET_RECRUITING

Yeungnam University Medical Center, Daegu

02841

RECRUITING

Korea University Anam Hospital, Seoul